What is Plasma Medicine ?
Plasma medicine leverages a safe, ionized gas like helium or air to accelerate healing, control infections, and treat skin conditions without drugs or invasive procedures. By harnessing reactive oxygen and nitrogen species (RONS), plasma therapies stimulate the body’s natural repair processes and directly disrupt harmful pathogens.
How Does It Work?
Cold plasma interacts with tissue surfaces by generating reactive energy at the treatment site. This selectively affects pathogenic cells while preserving healthy tissue integrity. The result is a non-invasive, contactless therapy that can:
• Reduce microbial load
• Promote wound repair
• Stimulate cellular recovery mechanisms
These effects arise from controlled oxidative interactions rather than thermal damage, making plasma a distinct modality from lasers or electrocautery.
Why Does it Matter?
Traditional antibiotics and wound care methods are increasingly limited by resistance, slow healing times, and invasive procedures. Cold plasma offers a complementary and drug-free approach that can:
• Help manage antibiotic-resistant infections
• Accelerate healing of chronic wounds
• Treat dermatological conditions safely and effectively
This technology opens new pathways in clinical care while reducing dependence on systemic drugs.
Why Plasma
A Different Way to Interact with Biology, Modern medicine relies on molecules.
Drugs require receptors. Chemistry requires pathways, Plasma operates differently.
It introduces physical energy at the biological interface using electric fields, reactive species, and charge interactions. This creates new ways to influence cells, microbes, tissues, and environments.
Plasma does not replace biology. It expands what biology can do.
At JivaJet, we're pioneering the use of cold plasma technology to revolutionize medical treatments.
Our focus is on developing innovative solutions that address antibiotic-resistant infections and promote rapid wound healing, offering drug-free, painless, and cost-effective therapies.
Mechanism
- Cold Atmospheric Plasma (CAP)
- Generates Oxygen and Nitrogen species
- Treats broad range of bacterial skin infections
- Promotes rapid wound healing
- FDA tested
Infected tissues exhibit elevated oxidative stress and distinct reactive oxygen and nitrogen species RONS profiles compared to healthy cells.
JivaJet applies cold atmospheric plasma containing RONS and electromagnetic waves for short duration localized exposure. This drives diseased cells beyond their oxidative threshold, triggering apoptosis while healthy cells tolerate the transient stress and return to homeostasis.
Plasma induced effects include targeted microbial DNA damage and membrane disruption. Following microbial reduction, tissue repair and cell proliferation may accelerate compared to untreated conditions.
Advantage
- Topical, non-Invasive, Painless
- Low cost
- Patented
- Rapid recovery time
- Reduce reliance on antibiotics
JivaMed is currently in the pre-revenue and pre-clinical research and development stages. Any images, animations, or computer-generated renderings shown are intended to illustrate envisioned features, potential capabilities, and future use cases of JivaJet’s plasma-based technologies. These products have not been reviewed or approved by the U.S. FDA and are not currently available for commercial sale. All forward-looking statements are based on preliminary research and management’s current understanding, and are subject to change without notice.
Fields of Use
Cancer and Oncology
Translational Plasma Research
Cancer cells have altered metabolism and reduced tolerance to oxidative stress. JivaJet is advancing cold atmospheric plasma CAP to study targeted biological interactions across in vitro preclinical and early clinical settings.
Research Focus
• Cancer cell line studies and glioblastoma models
• Apoptosis and stress signaling
• Tumor surface and microenvironment interactions
Clinical Context
Early human studies focus on safety and mechanism. CAP remains investigational and is not a standalone treatment.
Rare Genetic Disorders NF1 and TSC
Early Clinical Research
NF1 and TSC involve abnormal cell growth with limited localized options. JivaJet is evaluating CAP as a localized bio interaction modality.
Research Focus
• In vitro and preclinical studies
• First in human feasibility
• Plasma tissue interaction and safety
Clinical Context
Not FDA approved. Further trials required.
Mechanism
Cold plasma generates reactive species that selectively induce stress in diseased cells while sparing healthy tissue. CAP acts as a localized controllable bio interaction platform.
Areas of Investigation
• Adjunct oncology applications
• Tumor surface and margin models
• Apoptosis pathways
• Combination therapies
Anti Microbial Resistance and Multi Drug Resistance
Plasma Based Antimicrobial Research
Antimicrobial resistance and multidrug resistant infections are outpacing antibiotic development, driven by biofilms and reduced drug susceptibility.
JivaJet is advancing cold atmospheric plasma CAP as a non antibiotic modality enabling localized microbial inactivation through physical and chemical interactions.
Research Focus
• In vitro validation against drug resistant organisms
• Biofilm disruption at the surface level
• Microbial membrane and DNA damage analysis
• Resistance agnostic antimicrobial mechanisms
Plasma generated reactive species act through multi target pathways, reducing the likelihood of resistance.
Translational Context
Plasma technologies are being evaluated as complementary infection control strategies and are not FDA approved for clinical use.
Clinical Context
Resistant infections such as MRSA increasingly require surgical intervention. Plasma offers a localized non antibiotic approach for surface level infection control.
Rising resistance in pathogens like MRSA and Acinetobacter baumannii continues to challenge treatment. Plasma enables targeted action without systemic exposure.
Recurring infections in humans and animals are often driven by biofilms. Plasma based approaches provide a non invasive outpatient option that supports infection control while preserving surrounding tissue.
Wound Healing
Plasma-Assisted Tissue Response and Regeneration Research
Chronic and non-healing wounds are often driven by a combination of microbial burden, impaired cellular signaling, and reduced tissue regeneration capacity. These wounds frequently fail to respond to standard care, resulting in prolonged healing times and increased complication risk.
JivaJet investigates cold atmospheric plasma as a localized, non-invasive research platform to study how controlled plasma exposure influences wound environments and tissue response.
Research Progress
Plasma wound-healing research includes:
• Pre-clinical animal models evaluating wound closure dynamics
• Plasma effects on fibroblast migration and proliferation
• Reduction of microbial load at wound surfaces
• Investigation of oxygenation and signaling pathways involved in tissue repair
Plasma enables surface-level biological interaction without thermal damage or chemical exposure.
Clinical Context
Wound-healing applications of plasma are under translational investigation and are not approved clinical therapies. Research focuses on biological response, safety, and feasibility rather than clinical outcomes.
Chronic wounds like diabetic ulcers affect millions and often fail to heal with standard of care.
Conditions such as diabetic ulcers and pressure sores often fail to heal with standard care.
Cold plasma supports rapid re-epithelialization and reduce recovery times.
Decontamination and Sterilization
Plasma Based Decontamination
Cold atmospheric plasma CAP enables rapid chemical free decontamination by generating reactive species at ambient temperatures that disrupt microbial membranes proteins and genetic material without damaging underlying surfaces.
Unlike traditional methods that rely on heat chemicals or long exposure times plasma provides localized and efficient inactivation suitable for sensitive environments.
Use Cases
• Medical equipment and device surfaces
• Hospital rooms and high touch areas
• Laboratory and biosafety environments
• Emergency response and field operations
• Spaceflight and planetary protection
Plasma is particularly effective where chemical residues moisture or heat exposure are not acceptable. It does not clean surfaces but inactivates biological threats at the molecular level.
Context
Healthcare and research environments face increasing challenges from resistant organisms biofilms chemical toxicity and slow sterilization cycles. Plasma offers a complementary approach that reduces reliance on chemicals while improving speed and safety.
Astrobiology and Seed Germination
Plasma Research for Extreme Environments
Astrobiology examines how biological systems respond and survive in extreme environments such as radiation exposure low pressure and nutrient limited conditions.
JivaJet is investigating cold atmospheric plasma CAP as a research tool to study its impact on seed germination early plant development and microbial interactions under simulated extraterrestrial conditions.
Research Focus
• Plasma assisted seed surface activation
• Germination in lunar and Martian soil simulants
• Microbial load management without chemicals
• Early stage plant stress response signaling
• Biological resilience under simulated space conditions
Plasma provides a non thermal non chemical approach to influence biological systems at the surface level, making it well suited for space biology research.
Scientific Context
Plasma does not genetically modify organisms. Research focuses on surface level physical and biochemical interactions including wettability microbial reduction and early stage signaling that may influence growth outcomes.
Context
Extreme environments limit the use of chemicals heat and traditional agricultural methods. Plasma offers a controlled approach to support biological viability in resource constrained settings.
This research is relevant to long duration spaceflight planetary habitation and closed loop life support systems.
Development Status
All work remains investigational and pre clinical. Plasma technologies are not approved for agricultural or medical use and continue to undergo research and validation.